As of June 10, 2025, Immune Pharmaceuticals Inc (IMNPQ) reports a Net Margin of -1177500.00%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Immune Pharmaceuticals Inc's Net Margin
Over recent years, Immune Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2017-12-31 | -1177500.00% |
| 2016-12-31 | -1177500.00% |
| 2015-12-31 | -30315.79% |
| 2014-12-31 | -32.95% |
| 2013-12-31 | -1665.96% |
This slight downward trend highlights how Immune Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Immune Pharmaceuticals Inc's Net Margin to Peers
To better understand Immune Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Immune Pharmaceuticals Inc (IMNPQ) | -1177500.00% |
| Forward Pharma A/S (FWP) | 73.37% |
| Protalix Biotherapeutics Inc (PLX) | 5.49% |
| Globeimmune Inc (GBIM) | -42.85% |
| Lattice Biologics Ltd (LBL.V) | -60.16% |
| Sangui Biotech International Inc (SGBI) | -85.72% |
Compared to its competitors, Immune Pharmaceuticals Inc's Net Margin is lower than all peers, which may indicate challenges in controlling expenses or competitive pricing pressures.